Focused Ultrasound Therapy to Augment Antigen Presentation and Immune-Specificity of Checkpoint Inhibitor Therapy With Pembrolizumab in Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms Breast-48
- 08 May 2019 Planned primary completion date changed from 16 Sep 2019 to 16 Sep 2020.
- 31 Aug 2018 Biomarkers information updated
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.